Novonesis Lifts 2026 Sales Growth Outlook to 7–8% After Strong H1

Novonesis posted 8% organic sales growth — excluding acquisitions and currency effects — and a 37.7% adjusted EBITDA margin in H1 2026. It raised its full-year sales growth outlook from 5–7% to 7–8%, with margins expected near 38%. H1 topped February guidance, which had accounted for currency headwinds after a Q4 2025 miss. (Source: Novonesis, Aug 19, 2026)